We need your input to improve Horizon 2020 and the next Research and Innovation Framework Programme of the European Union.
The European Commission is planning the interim evaluation of Horizon 2020 which will be crucial to the future of biomedical research funding in Europe. To influence this process, we, the biomedical research community, must feed your and your colleagues’ experiences and opinions with Horizon 2020 into this evaluation.
- The survey should take approximately 10 minutes of your time.
- Please ask your colleagues to fill out this survey as well. This makes the survey better and increases the volume of our ‘voice’.
- Your input will help us to provide European institutions with strategic recommendations.
- We look forward to receiving your answers no later than October 22, 2015.
So, if you have or have had any experience with Horizon 2020, you are kindly asked to fill out the survey here: https://www.surveymonkey.com/r/H2020evaluation
Thank you for your support.
With kind regards, sincerely,
Professor Ulrich Jäger
Chair of the EHA EU Affairs Committee
Member of the BioMed Alliance Board of Directors and
Chair of the Monitoring Horizon 2020 Task Force
The Alliance for Biomedical Research in Europe (Biomed Alliance)
The Alliance for Biomedical Research in Europe (BioMed Alliance) is a unique initiative representing 21 leading European biomedical societies that together include more than 400,000 researchers and health professionals across Europe.
The organization’s aim is to facilitate and promote excellence in health and biomedical research, through advocacy and specific actions, at European level.
On October 6, 2015, the Innovative Medicines Initiative (IMI) launched its 6th Call for proposals under IMI 2. This call includes, under the program “Big Data for Better Outcomes programme”, the topic:
Development of an outcomes-focused platform to empower policy makers and clinicians to optimize care for patients with hematologic malignancies.
Vienna, June 12, 2015 – Promising results from an early phase trial combining the anti-bcl-2 drug Venetoclax with Rituximab to eliminate CLL are presented by Dr Andrew Roberts.
Vienna, June 12, 2015 – On behalf of the EUTOS network, Dr Hoffmann will present data of a web-based registry of newly diagnosed CML patients.
Vienna, June 12, 2015 – On behalf of the ELOQUENT-2 investigators, Dr Dimopoulos will present the positive results on Elotuzumab with Lenalidomide from a phase III study in patients with multiple myeloma.
Vienna, June 12, 2015 –Dr Guryanova will present a new mechanism for chemoresistance in AML based on acquired DNA mutations.
Vienna, June 12, 2015 –Dr Marneth will discuss the findings of eight new genetic variants in GFI1B that have been discovered in patients with bleeding and platelet disorders and consequences for new therapeutic targets.
Vienna, June 12, 2015 –Dr Mesa will present new data from the phase 3 PERSIST-1 study on improving disease symptoms and quality of life for patients with myelofibrosis.
Vienna, June 12, 2015 – Dr Ehninger will present the results of a phase II randomized study on the safety and efficacy of Sorafenib.
At the Congress of the European Hematology Association (EHA) – attracting 10,000 hematologists from Europe and beyond - the president of EHA, Prof. Christine Chomienne, called upon the European Union to deliver funding for Research into Blood Disorders:
“The hematologists in Europe have done a great work. Now it’s the EU’s turn to deliver.”